QuVa Pharma, Inc. recalls R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Vo
Recalled November 5, 2025 · FDA recall D-0113-2026 · QuVa Pharma
Hazard
Presence of Particulate Matter · FDA Class II
Units
75,885 syringes
Sold at
U.S. Nationwide
Description
Presence of Particulate Matter
Product
R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50
Manufacturer(s)
QuVa Pharma, Inc.
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →